Uniquity Bio

At Uniquity Bio, we are actively building our immunology and inflammation pipeline.     Learn more about partnering with #TeamUniquity here: https://bit.ly/3Al0z2t    #Biotech #Immunology 

As a nimble startup with a proven #team of experts in drug development, Uniquity is well-positioned to deliver promising therapeutics in #immunology and #inflammation. We are uniquely designed to partner with leading global pharmaceutical companies and bring important new medicines to patients. See our pipeline: https://bit.ly/3Yfz6ZF    #Biotech #BioPharma 

Backed by Blackstone Life Sciences, we have the resources to deliver innovative medicines to #patients. Partner with us: https://bit.ly/3Al0z2t #Innovation #Success

People with #asthma continue to have significant unmet needs despite the variety of therapeutics available. Our goal is for our lead asset solrikitug to offer another treatment option that improves patient outcomes by effectively targeting TSLP – which sits at the top of the inflammatory cascade. Solrikitug is now in Phase 2 clinical trials for asthma and COPD. See our pipeline: https://bit.ly/3Yfz6ZF    #Biotech #BioPharma

The #culture at Uniquity Bio mirrors one of our core values: put patients and science first. Hector Ortega, Andrew Lee and Kelly Copeland explain how our culture supports our focus on addressing the unmet needs of #patients.    Meet #TeamUniquity: https://bit.ly/4cb80Gw

Uniquity Bio is built to continually develop #biopharma assets, partnering them as they mature, and bringing in new programs that align to our strategic goals. Find out more: https://bit.ly/3LsUZx6 #Science #Medicine #Leadership 

Uniquity Bio is strategically targeting chronic obstructive pulmonary disease, or #COPD. Beyond COPD, we believe solrikitug, our lead candidate, has potential utility in a wide array of immunology and inflammation programs.    See progress in our pipeline: https://bit.ly/4cSDMZx   #BioPharma #Patients #Innovation

Uniquity Bio is a clinical-stage drug development company built by industry executives with a proven track record. We seek to advance therapeutic programs in #immunology and #inflammation with a laser focus on improving patients’ lives. Meet our seasoned team: https://lnkd.in/g8Y9X_9B #TeamUniquity #Patients #Leadership

Solrikitug, our lead asset, is a human monoclonal antibody, currently in Phase 2 #clinical trials, targeting TSLP that offers broad therapeutic potential in immunology and inflammation. We aim to deliver best-in-class efficacy with solrikitug across several critical respiratory and gastrointestinal indications with significant unmet needs, including #COPD and #asthma.    Learn about solrikitug here: https://bit.ly/3TONe8j     #BioPharma #Science #Healthcare 

At Uniquity Bio, we aim to deliver best-in-class medicines to patients and industry partners while creating value for investors.    Our approach to drug development is built on decades of clinical, development, and regulatory experience and supported by Blackstone Life Sciences. We’re dedicated to the same high standards of scientific rigor and clinical quality upheld by global pharma companies, while our operational agility gives us a competitive edge.     Learn more about how we can work together: https://bit.ly/4eulBeA    #BioPharma #Healthcare #Innovation